| Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. Sci Rep
                         11:
                    		 2021
                    		 8856
 | 9 | 
                   
                     
                       | Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat Commun
                         12:
                    		 2021
                    		 3904
 | 65 | 
                   
                     
                       | Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Sci Adv
                         8:
                    		 2022
                    		 eabm1831
 | 58 | 
                   
                     
                       | Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Front Oncol
                         12:
                    		 2022
                    		 954430
 | 2 | 
                   
                     
                       | A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell
                         58:
                    		 2023
                    		 1106-1121.e7
 | 12 | 
                   
                     
                       | Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma. BMC Cancer
                         24:
                    		 2024
                    		 173
 | 1 | 
                   
                     
                       | Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level. Sci Rep
                         14:
                    		 2024
                    		 4322
 | 0 | 
                   
                     
                       | In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications. Nat Commun
                         15:
                    		 2024
                    		 7039
 | 1 |